S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10

Zealand Pharma A/S Stock Forecast, Price & News

0.00 (0.00%)
(As of 01/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
155 shs
Average Volume
4,504 shs
Market Capitalization
$816.30 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Zealand Pharma A/S logo

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design and development of peptide based medicines. Its products include Soliqua and Lyxumia. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Soborg, Denmark.


Zealand Pharma A/S (NASDAQ:ZEAL) Sees Strong Trading Volume
January 25, 2022 |  americanbankingnews.com
Zealand Pharma A/S (NASDAQ:ZEAL) Reaches New 1-Year Low at $18.93
January 24, 2022 |  americanbankingnews.com
Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Down to $21.22
January 21, 2022 |  americanbankingnews.com
Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Up to $21.74
January 12, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$54.13 million
Book Value
$4.73 per share


Net Income
$-129.72 million
Net Margins
Pretax Margin




Free Float
Market Cap
$816.30 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

0.88 out of 5 stars

Medical Sector

1317th out of 1,417 stocks

Pharmaceutical Preparations Industry

641st out of 683 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Zealand Pharma A/S (NASDAQ:ZEAL) Frequently Asked Questions

Is Zealand Pharma A/S a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zealand Pharma A/S stock.
View analyst ratings for Zealand Pharma A/S
or view top-rated stocks.

How has Zealand Pharma A/S's stock been impacted by COVID-19 (Coronavirus)?

Zealand Pharma A/S's stock was trading at $28.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZEAL stock has decreased by 33.4% and is now trading at $18.7079.
View which stocks have been most impacted by COVID-19

Are investors shorting Zealand Pharma A/S?

Zealand Pharma A/S saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 165,800 shares, an increase of 24.5% from the December 15th total of 133,200 shares. Based on an average trading volume of 5,200 shares, the short-interest ratio is presently 31.9 days.
View Zealand Pharma A/S's Short Interest

When is Zealand Pharma A/S's next earnings date?

Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Zealand Pharma A/S

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) issued its earnings results on Wednesday, November, 10th. The company reported ($4.61) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($6.31) by $1.70. The firm earned $16.87 million during the quarter, compared to the consensus estimate of $12.21 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 82.62% and a negative net margin of 371.32%. During the same quarter last year, the company earned ($0.90) EPS.
View Zealand Pharma A/S's earnings history

Who are Zealand Pharma A/S's key executives?

Zealand Pharma A/S's management team includes the following people:
  • Emmanuel Dulac, President & Chief Executive Officer
  • Ivan M. Møller, Senior VP-Technical Development & Operations
  • Matthew D. Dallas, Chief Financial Officer & Senior Vice President
  • Adam Sinding Steensberg, Chief Medical Officer, EVP-Research & Development
  • Danilo Verge, Head-Global Medical Affairs

What other stocks do shareholders of Zealand Pharma A/S own?

When did Zealand Pharma A/S IPO?

(ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL."

How do I buy shares of Zealand Pharma A/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zealand Pharma A/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $18.71.

How much money does Zealand Pharma A/S make?

Zealand Pharma A/S has a market capitalization of $816.30 million and generates $54.13 million in revenue each year. The company earns $-129.72 million in net income (profit) each year or ($4.34) on an earnings per share basis.

How many employees does Zealand Pharma A/S have?

Zealand Pharma A/S employs 329 workers across the globe.

What is Zealand Pharma A/S's official website?

The official website for Zealand Pharma A/S is www.zealandpharma.com.

Where are Zealand Pharma A/S's headquarters?

Zealand Pharma A/S is headquartered at SYDMARKEN 11, COPENHAGEN G7, 2860.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The company can be reached via phone at (458) 877-3600, via email at [email protected], or via fax at 45-8877-3898.

This page was last updated on 1/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.